How does kidney disease affect tirzepatide's benefits in obese heart failure patients?
Chronic kidney disease made heart failure worse in obese patients, but tirzepatide still improved heart failure outcomes regardless of kidney function—and creatinine-based kidney tests may underestimate how well tirzepatide actually improves kidney function.
Quick Facts
What This Study Found
Tirzepatide improved heart failure outcomes equally in patients with and without CKD, but creatinine-based eGFR appeared to decline on tirzepatide while cystatin C-based eGFR improved—indicating the creatinine decline is an artifact of muscle loss from weight reduction, not true kidney deterioration.
Key Numbers
- 731 SUMMIT trial patients, enriched for CKD
- CKD patients had 2x risk of worsening heart failure events
- Baseline eGFR-cystatin C was ~9 mL/min/1.73m2 lower than eGFR-creatinine
- Tirzepatide improved eGFR at 52 weeks by both measures
- eGFR-creatinine dipped at 12 weeks then recovered; eGFR-cystatin C improved throughout
How They Did This
Pre-specified sub-analysis of the SUMMIT RCT (n=731); CKD subgroup analyses stratified by creatinine- and cystatin C-based eGFR; eGFR measured at baseline, 12, 24, and 52 weeks; KCCQ-CSS and cardiovascular outcomes as endpoints.
Why This Research Matters
Millions of patients with obesity have both CKD and HFpEF simultaneously. Understanding that tirzepatide benefits extend to CKD patients—and that conventional kidney tests may mislead clinicians about drug safety—has immediate clinical relevance for monitoring and prescribing decisions.
The Bigger Picture
The measurement discrepancy between creatinine and cystatin C when weight loss occurs is a broadly important issue for all GLP-1 and GLP-1/GIP trials. This finding suggests current prescribing guidelines may need to be updated to prefer cystatin C-based monitoring in patients on these drugs.
What This Study Doesn't Tell Us
Subgroup analysis from an RCT—not powered for CKD-specific endpoints. Cystatin C measurement was not part of the original trial design and required post-hoc analysis. Generalizability to non-obese or non-HFpEF CKD populations is unclear.
Questions This Raises
- ?Should cystatin C replace creatinine as the standard kidney marker in all GLP-1/GIP drug trials?
- ?Does tirzepatide provide direct kidney protection beyond what is explained by weight loss?
- ?Can this same measurement artifact affect other metabolic drugs that cause substantial weight loss?
Trust & Context
- Key Stat:
- 2× Higher baseline risk of cardiovascular death or heart failure events in CKD patients compared to non-CKD patients in the SUMMIT trial
- Evidence Grade:
- Rated strong as a pre-specified sub-analysis of a large international RCT (SUMMIT), though CKD-specific endpoints were not the primary trial objective.
- Study Age:
- Published in 2025 in the Journal of the American College of Cardiology; part of the SUMMIT trial dataset.
- Original Title:
- Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity: The SUMMIT Trial.
- Published In:
- Journal of the American College of Cardiology, 85(18), 1721-1735 (2025)
- Authors:
- Packer, Milton(6), Zile, Michael R(6), Kramer, Christopher M(5), Murakami, Masahiro, Ou, Yang, Borlaug, Barry A
- Database ID:
- RPEP-12911
Evidence Hierarchy
Participants are randomly assigned to treatment or placebo groups to test cause and effect.
What do these levels mean? →Frequently Asked Questions
Why does creatinine go down on tirzepatide even if kidneys aren't getting worse?
Creatinine is a waste product from muscle. When tirzepatide causes weight loss and muscle mass decreases, less creatinine is produced—making kidneys appear to decline on standard tests even when they may actually be improving.
Is tirzepatide safe for patients with kidney disease?
Based on SUMMIT data, yes—tirzepatide provided consistent heart failure benefits in CKD patients and did not appear to harm kidney function when measured with the more accurate cystatin C marker.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-12911APA
Packer, Milton; Zile, Michael R; Kramer, Christopher M; Murakami, Masahiro; Ou, Yang; Borlaug, Barry A. (2025). Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity: The SUMMIT Trial.. Journal of the American College of Cardiology, 85(18), 1721-1735. https://doi.org/10.1016/j.jacc.2025.03.009
MLA
Packer, Milton, et al. "Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity: The SUMMIT Trial.." Journal of the American College of Cardiology, 2025. https://doi.org/10.1016/j.jacc.2025.03.009
RethinkPeptides
RethinkPeptides Research Database. "Interplay of Chronic Kidney Disease and the Effects of Tirze..." RPEP-12911. Retrieved from https://rethinkpeptides.com/research/packer-2025-interplay-of-chronic-kidney
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.